BRVE Braveheart Bio, Inc.: institutional ownership and insider trading
1 funds reported holding $202 of Braveheart Bio, Inc. in their latest 13F filings; over the last 12 months insiders bought $159M and sold $0 on the open market.
BRVE revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$15.0M, EPS -2.51
- Quarter ended Mar 31, 2026: revenue n/a, net income −$14.3M
- Quarter ended Jun 30, 2025: revenue n/a, net income −$381K, EPS -0.14
- Quarter ended Mar 31, 2025: revenue n/a, net income −$99.0K
Largest institutional holders of BRVE
- SBI Securities Co., Ltd. — $202
Recent BRVE insider trades
- Aug 7, 2026: Chimovits Erez bought 1,940,000 shares ($34.9M)
- Aug 7, 2026: Orbimed Advisors Llc bought 1,940,000 shares ($34.9M)
- Aug 7, 2026: Andreessen Marc L bought 1,100,000 shares ($19.8M)
- Aug 7, 2026: Lubner David Charles bought 55,555 shares ($1000K)
5%+ owners
- ORBIMED ADVISORS LLC: 13.5% (Schedule 13D/A, filed Sep 10, 2026)
- AH Bio Fund IV, L.P.: 11.4% (Schedule 13D, filed Aug 14, 2026)
- Frazier Life Sciences Public Fund, L.P.: 5.5% (Schedule 13G, filed Aug 14, 2026)
Who owns the most BRVE stock?
The largest institutional holders of Braveheart Bio, Inc. in the latest 13F filings are SBI Securities Co., Ltd. ($202).
Are insiders buying or selling BRVE?
Over the last 12 months insiders bought $159M and sold $0 of Braveheart Bio, Inc. stock on the open market (SEC Form 4).